---
title: "Impact of population-level alcohol reduction to low-risk drinking on anxiety and depression preval"
id: "medrxiv-21-prevalence-of-anxiety-and-depression-symptoms-under-population-level-alcohol"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-21-prevalence-of-anxiety-and-depression-symptoms-under-population-level-alcohol"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.31.26359417v1?rss=1"
published_at: "2026-08-03T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Impact of population-level alcohol reduction to low-risk drinking on anxiety and depression preval
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-21-prevalence-of-anxiety-and-depression-symptoms-under-population-level-alcohol
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.31.26359417v1?rss=1)
- **Published At:** 2026-08-03T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This US national longitudinal cohort study used data from 2,813 adults without documented underlying health conditions collected September 2021–December 2023 to estimate how reducing alcohol consumption to **low-risk drinking** would affect population prevalence of moderate-to-severe **depression** and **anxiety** symptoms. - The authors emulated a target trial and applied the **parametric g-formula** to address time-varying confounding, reverse causation, and health-related selection into abstinence. - The hypothetical intervention set moderate- and high-risk drinking to low-risk at each follow-up while leaving abstinence and existing low-risk drinking unchanged. - Outcomes were moderate-to-severe depressive symptoms (PHQ-8 ≥10) and anxiety symptoms (GAD-7 ≥10); models adjusted for baseline and time-varying covariates and used bootstrap resampling to estimate uncertainty. - Under the natural course the estimated prevalence of moderate-to-severe depression was 12.67% (95% CI: 12.17, 13.23); under the intervention it was 12.77% (95% CI: 12.26, 13.29), risk difference 0.10 percentage points (95% CI: -0.22, 0.50). - For anxiety, prevalence under the natural course was 10.40% (95% CI: 8.89, 11.89) versus 10.25% (95% CI: 8.76, 11.98) under the intervention; risk difference -0.15 percentage points (95% CI: -0.68, 0.35). - The estimated differences were near null, suggesting that a population-wide reduction of alcohol use to low-risk levels alone may be insufficient to substantially change the population burden of common mental disorders. - Authors disclose DN received consulting fees from AbbVie and Gilead and has a research grant from Pfizer to his institution; other authors declare no conflicts and funders did not influence study design or reporting. - Data and code are available in a Zenodo repository (DOI reported) with some elements restricted per funder requirements; IRB approval was obtained from the CUNY Graduate School of Public Health Institutional Review Board. - The report is a preprint and has not been peer reviewed; it should not be used to guide clinical practice.
## Clinical Analysis & Structured Key Points
Prevalence of anxiety and depression symptoms under population-level alcohol reduction to low-risk drinking: A parametric g-computation analysis in a U.S. nationwide cohort | medRxiv Skip to main content Prevalence of anxiety and depression symptoms under population-level alcohol reduction to low-risk drinking: A parametric g-computation analysis in a U.S. nationwide cohort View ORCID Profile Jenna Sanborn , View ORCID Profile Denis Nash , View ORCID Profile McKaylee Robertson , View ORCID Profile Angela Parcesepe , View ORCID Profile Zachary Shahn doi: https://doi.org/10.64898/2026.07.31.26359417 Jenna Sanborn 1 Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States.; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jenna Sanborn For correspondence: jenna.sanborn{at}sph.cuny.edu Denis Nash 1 Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States.; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Denis Nash McKaylee Robertson 1 Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States.; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for McKaylee Robertson Angela Parcesepe 2 University of North Carolina at Chapel Hill Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Angela Parcesepe Zachary Shahn 1 Institute for Implementation Science in Population Health, City University of New York, Graduate School of Public Health and Health Policy, New York, NY, United States.; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Zachary Shahn Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Alcohol consumption is a modifiable risk factor linked to anxiety and depression, yet the population-level impact of reducing alcohol use on the prevalence of anxiety and depression symptoms remains unclear. Prior studies are limited by methodological challenges including health-related selection into abstinence, time-varying confounding and reverse causation. Methods: We used data from 2,813 participants without documented underlying health conditions in a U.S. national longitudinal cohort (September 2021-December 2023) and applied the parametric g-formula within a target trial emulation framework to estimate the effect of a hypothetical intervention reducing alcohol consumption to low-risk levels on the prevalence of moderate-to-severe anxiety (GAD-7 ≥10) and depression (PHQ-8 ≥10) symptoms. The intervention set moderate- and high-risk drinking to low-risk at each follow-up, while leaving abstinent and low-risk drinking unchanged. Models adjusted for time-varying and baseline covariates, with uncertainty estimated using bootstrap resampling. Results: Under the natural course, the estimated prevalence of moderate-to-severe depressive symptoms was 12.67% (95% CI: 12.17, 13.23), compared to 12.77% (95% CI: 12.26, 13.29) under the intervention (risk difference: 0.10 percentage points; 95% CI: -0.22, 0.50). For anxiety symptoms, prevalence was 10.40% (95% CI: 8.89, 11.89) under the natural course and 10.25% (95% CI: 8.76, 11.98) under the intervention (risk difference: -0.15 percentage points; 95% CI: -0.68, 0.35). Conclusions: Under a hypothetical population-wide intervention reducing alcohol consumption to low-risk levels, differences in the prevalence of moderate or severe anxiety and depression symptoms were near null. These findings suggest that reducing alcohol use alone may be insufficient to meaningfully shift the population-wide burden of common mental health disorders. Competing Interest Statement DN received consulting fees from Abbvie and Gilead and has a research grant from Pfizer for his institution (CUNY SPH). The other authors declare no conflict of interest. The funders had no role in the design of this study, in the collection, analysis, or interpretation of data, in the writing of this manuscript, or in the decision to publish these results. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Board at CUNY Graduate School of Public Health gave ethical approval of this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The datasets generated and/or analyzed during the current study are available in the repository, Zenodo: DOI: 10.5281/zenodo.6127734. Some data elements are not publicly available due to funder requirements, but are available from the authors upon reasonable request, subject to approval and available resources. https://zenodo.org/records/7305435 Funder Information Declared National Institute of Allergy and Infectious Diseases (NIAID) , UH3AI133675 National Institute of Mental Health, https://ror.org/04xeg9z08 , RF1MH132360 National Institute of Child Health and Human Development , P2C HD050924 Pfizer (United States), https://ror.org/01xdqrp08 CUNY Institute for Implementation Science in Population Health CUNY Graduate School of Public Health and Health Policy Department of Epidemiology and Biostatistics COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted August 03, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Prevalence of anxiety and depression symptoms under population-level alcohol reduction to low-risk drinking: A parametric g-computation analysis in a U.S. nationwide cohort Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Prevalence of anxiety and depression symptoms under population-level alcohol reduction to low-risk drinking: A parametric g-computation analysis in a U.S. nationwide cohort Jenna Sanborn , Denis Nash , McKaylee Robertson , Angela Parcesepe , Zachary Shahn medRxiv 2026.07.31.26359417; doi: https://doi.org/10.64898/2026.07.31.26359417 Share This Article: Copy Citation Tools Prevalence of anxiety and depression symptoms under population-level alcohol reduction to low-risk drinking: A parametric g-computation analysis in a U.S. nationwide cohort Jenna Sanborn , Denis Nash , McKaylee Robertson , Angela Parcesepe , Zachary Shahn medRxiv 2026.07.31.26359417; doi: https://doi.org/10.64898/2026.07.31.26359417 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Epidemiology Subject Areas All Articles Addiction Medicine (594) Allergy and Immunology (887) Anesthesia (322) Cardiovascular Medicine (4679) Dentistry and Oral Medicine (465) Dermatology (402) Emergency Medicine (631) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1593) Epidemiology (15645) Forensic Medicine (32) Gastroenterology (1176) Genetic and Genomic Medicine (6876) Geriatric Medicine (714) Health Economics (1034) Health Informatics (4852) Health Policy (1411) Health Systems and Quality Improvement (1699) Hematology (568) HIV/AIDS (1304) Infectious Diseases (except HIV/AIDS) (16145) Intensive Care and Critical Care Medicine (1144) Medical Education (650) Medical Ethics (148) Nephrology (704) Neurology (7026) Nursing (357) Nutrition (1056) Obstetrics and Gynecology (1206) Occupational and Environmental Health (988) Oncology (3509) Ophthalmology (1015) Orthopedics (381) Otolaryngology (432) Pain Medicine (454) Palliative Medicine (135) Pathology (695) Pediatrics (1752) Pharmacology and Therapeutics (724) Primary Care Research (751) Psychiatry and Clinical Psychology (5721) Public and Global Health (9551) Radiology and Imaging (2323) Rehabilitation Medicine and Physical Therapy (1406) Respiratory Medicine (1227) Rheumatology (628) Sexual and Reproductive Health (756) Sports Medicine (567) Surgery (750) Toxicology (105) Transplantation (299) Urology (278)
## Related Clinical Research

- [Nurse Practitioner Trainees Face Clinical Mentor Shortage and Preceptor Challenges](https://medichelpline.com/clinical-feed/stat-news-3-nurse-practitioner-trainees-find-themselves-stymied-by-shortage-of-clinical.md)
- [Limits of Postpartum Psychiatry Revealed by the Lindsay Clancy Case](https://medichelpline.com/clinical-feed/stat-news-1-opinion-the-lindsay-clancy-case-shows-the-limits-of-postpartum-psychiatry.md)
- [Impact of Drug Decriminalization on Mental Health: Insights from Oregon and Washington](https://medichelpline.com/clinical-feed/medrxiv-1-drug-decriminalization-and-population-mental-distress-evidence-from-oregon-and.md)
- [Physical activity alters how alcohol use relates to anxiety and depression symptoms in a US cohort](https://medichelpline.com/clinical-feed/medrxiv-16-the-role-of-physical-activity-in-shaping-the-relationship-between-alcohol-use.md)
- [2026 Stroke Rehabilitation Guideline: Start Early and Address Physical, Cognitive, and Mental Heal](https://medichelpline.com/clinical-feed/medical-news-today-0-stroke-rehab-guidelines-emphasize-early-support-for-physical-cognitive-and.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.